Present and future outlook for dendritic cell (DC)-based vaccine against cancer

Mitsuo Katano, Takashi Morisaki, Mitsunari Nakamura, Kohtaro Matsumoto, Akira Tasaki, Masafumi Nakamura

Research output: Contribution to journalArticle


We propose that tumors discovered in a clinical setting are already in the world of immune tolerance. In order to induce powerful antitumor immunity, therefore, we will have to develop a new immune surveillance system in the body. We focused on the ongoing noteworthy devices to improve antigen-presenting ability of dendritic cells (DCs) which play a key role in the world of immune surveillance. One approach is to develop strategies capable of prolonging both the activation state and life span of DCs. A second way is to adjust the immunological environment of tumor sites to the immune surveillance world. Finally, we briefly introduce the ongoing trials concerning artificial antigen-presenting systems.

Original languageEnglish
Pages (from-to)330-338
Number of pages9
Issue number4
Publication statusPublished - Jul 1 2005


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Katano, M., Morisaki, T., Nakamura, M., Matsumoto, K., Tasaki, A., & Nakamura, M. (2005). Present and future outlook for dendritic cell (DC)-based vaccine against cancer. Biotherapy, 19(4), 330-338.